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Abstract
Themean (SD) unbound fraction ofmoxifloxacin in plasma from patients
with severe sepsis or septic shock was determined by ultrafiltration to
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Introduction
Moxifloxacin is a fluoroquinolone with excellent activity
against a broad spectrum of microorganisms involved in
soft tissue infections [1]. Total tissue concentrations of
moxifloxacin reach or exceed the corresponding plasma
concentrations [2]. However, concentrations determined
in tissue homogenate should be interpreted with caution,
most importantly because no distinction can be made
between the intra- and extracellular concentrations [3],
[4]. Particularly, high concentrations of fluoroquinolones
in tissue homogenate could be due to enrichment within
the cells, whereas most bacterial infections occur in the
extracellular space [4]. Therefore, measurement of inter-
stitial concentrations, e.g. by microdialysis, is to be pre-
ferred whenever possible [5]. As the interstitial concen-
trations are basically free drug concentrations, the com-
bination of measurement of the free plasma concentra-
tions and the interstitial concentrations is the best way
to get reliable results on the tissue concentrations of
antibiotics and the tissue to plasma ratio.
Previous studies have demonstrated that rapid or com-
plete equilibration of antibiotics between plasma and
tissue cannot be taken for granted for each clinical setting
and patient population, particularly for those patients
who suffer from substantially impaired local or systemic
blood flow [6]. Hence, in the present study the kinetics
of moxifloxacin were investigated in plasma as well as in
interstitial fluid of patients with sepsis after single and
multiple dosing using microdialysis technique. Here we
report the results from the measurement of free moxi-
floxacin in plasma.
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Methods
Patients and study design
The plasma samples were obtained from a single-center
non-controlled pharmacokinetic study in adult ICU pa-
tients with severe sepsis or septic shock [7]. The aim of
the study was to assess the plasma and tissue pharma-
cokinetics of moxifloxacin using microdialysis. The study
was approved by the Ethics Committee of the Medical
Faculty of the Ruhr-University Bochum (reference no.
4830-13). Written informed consent was obtained from
either the patient or their legal representative. The pa-
tients receivedmoxifloxacin 400mg (Avalox 400mg/250
mL solution for infusion, Bayer Vital GmbH, D-51368
Leverkusen, Germany) once daily as one-hour infusion.
Arterial blood (LiHeparinmonovette, Sarstedt Nümbrecht,
Germany) and microdialysate was collected before infu-
sion (baseline) and up to 10 hours on day 1, 3 and 5 of
treatment. The blood was centrifuged and the plasma
separated. All samples were stored at –80°C for up to
12months, shipped to the analytical laboratory in dry ice
and then stored further at –70°C for up to 2 months be-
fore analysis.
Chemicals
Moxifloxacin hydrochloride (MXF-HCl) and Avalox
400 mg/250 mL (1 mL solution for infusion contains
1.6 mg/mL moxifloxacin) was obtained from Bayer Vital
GmbH, Leverkusen. The internal standard gatifloxacin
was obtained from Grünenthal GmbH, Aachen, Germany.
Acetonitrile and methanol (both HPLC gradient grade)
and the other chemicals were purchased from VWR,
Darmstadt, Germany. HPLC grade water was produced
with an Arium basic water purification system (Sartorius,
Göttingen, Germany). Blank plasma was obtained from
healthy volunteers.
Stock solutions, calibrators (STD), and
quality control samples
Moxifloxacin and gatifloxacin (IS) stock solutions
(100mg/L) were made in 0.01M hydrochloric acid (HCl).
Aliquots of the stock solutions were stored at –70°C and
thawed before use. Residuals of thawed solutions were
discarded. The standards (STD) and quality control (QC)
samples were prepared by dilution in 0.1M HCl/MeOH
70:30 (v/v) and finally 1:20 (v/v) with plasma. STDs and
QCs were stored at –70°C for no longer than 3 months
until use.
Sample preparation
Total moxifloxacin was determined in all blood samples
as published previously [8] with minor modifications. In
brief, 100 µL internal standard (iS) solution (gatifloxacin
1mg/L in 0.2%Na-EDTA, pH 6–7) wasmixed with 100 µL
plasma and 400 µL acetonitrile. Themixture was vortexed
for 2–3 seconds, incubated for 15 min at 4°C and cent-
rifuged. An aliquot (300 µL) of the supernatant was filled
into the HPLC vials and diluted with 300 µL 0.01M hydro-
chloric acid (in order to reduce peak broadening due to
the high elution strength of the injection solution). An
aliquot of 1–3 µL was injected into the HPLC system.
Intra- and inter-assay imprecision as well as accuracy,
based on in-process controls (2.5, 0.8 and 0.25 mg/L),
were <4% and 100%, respectively. The concentrations
of free moxifloxacin were determined by ultrafiltration
applying a published method [9] in part of patient
samples: prior to first administration (blank value), after
1 hour (end of infusion, high concentration) and after
10 hours (low concentration). In brief, 10 µL 3 M potassi-
um phosphate buffer, pH 7.5, was pipetted into the ultra-
filtration device (Nanosep Omega 10K, VWR, Darmstadt,
Germany) and mixed with 300 µL plasma. Following in-
cubation (10 min, 37°C, 100 g) in an Eppendorf 5417R
centrifuge (Eppendorf, Hamburg, Germany) and centrifu-
gation (20 min, 37°C, 1000 g), an aliquot (1–3 µL) of
the ultrafiltrate (70–90 µL) was injected into the HPLC
system. Unspecific adsorption of moxifloxacin to the UF
device was assessed by filtration of 400 µL moxifloxacin
10, 3, 1, 0.3, 0.1, 0.03 or 0.01 mg/L in 0.1 M potassium
phosphate buffer, pH 7.4 (2 min, 1000 g, ambient tem-
perature). The recovery of moxifloxacin was constant over
the whole range and amounted to 96.8±5.1% (mean±SD
of 3 dilution series with 7 concentrations each). The intra-
assay precision was not determined, as preliminary re-
sults revealed an intra-assay imprecision of <1%. The
unbound fraction of moxifloxacin in a control pool (spiked
with moxifloxacin 4 or 0.4 mg/L) from healthy volunteers
analysed with each run was 82.6±1.8% (n=5) which cor-
responds to an imprecision of 1.9%. The accuracy cannot
be specified, as the true value of the unbound fraction
of the drug in plasma is not known. The potential concen-
tration dependence of the protein binding of moxifloxacin
was examined/checked analysing 6 independent dilution
series in pooled plasma from healthy volunteers with
moxifloxacin 10, 3, 1, 0.3, 0.1, 0.03 and 0.01 mg/L.
Chromatography
Chromatography was performed on a ProminenceModu-
lar HPLC equipped with a fluorimetric detector RF10AXL,
set to ex/em 296/504 nm (Shimadzu, Duisburg, Ger-
many). The autosampler was cooled to 6°C, the column
temperature was 40°C. The separation system included
a guard column 4x3 mm filled with Nucleoshell RP 18,
2.7 µ silicagel and an analytical column Nucleodur C18
HTec 3 µ, 125x4 mm. The mobile phase consisted of
800ml water, 200ml acetonitrile, 1600mg tetrabutylam-
monium hydrogen sulfate, 800 µl phosphoric acid 85%,
pH 3.0 with sodium hydroxide. Gatifloxacin (iS) eluted
after 1.8 min and moxifloxacin after 2.4 min at a flow
rate of 0.8 mL/min.
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Statistical analysis
GraphPad Prism 6.0 for MacOSX (GraphPad Software,
La Jolla, CA, USA) was used for calculating nonparametric
or parametric descriptive statistics. Least square analysis
of dilution series was performed using the weighting
factor 1/y2. Data are presented as mean (±SD), median
or (interquartile) range, as appropriate. Unbound fraction
(fu) in pool plasma has been calculated asmeasured free
concentration/nominal concentration, whereas fu in pa-
tient plasma has been calculated as measured free con-
centration/measured total concentration in the respective
plasma sample.
Results
Unspecific binding of moxifloxacin onto the ultrafiltration
membrane was negligible. Therefore, the results are not
corrected for unspecific binding. The protein binding of
moxifloxacin in pool plasma from the healthy volunteers
was independent of the concentration. The dilution series
(range 10.0–0.01 mg/L) was perfectly linear (r=1.000,
y=0.843*x+0.000) revealing a mean unbound fraction
of 84.3%. Therefore, we considered it sufficient to
measure the free plasma concentrations of moxifloxacin
only in a part of the patient samples (after 1 hour and
after 10 hours). Additionally, as the total plasma concen-
trations of moxifloxacin were similar on day 1, 3 and 5
(peak concentrations averaged over all 10 patients were
3.16±0.27 mg/L at the end of infusion (1 hour) and
1.01±0.13 mg/L after 10 hours, respectively), the con-
centrations of each patient were averaged to calculate
the individual unbound fraction. Thus, themean unbound
fraction of moxifloxacin in plasma of the 10 patients was
85.5±3.0% (range 81.9 and 91.6%) with a mean intra-
individual coefficient of variation of 2.4% (Figure 1).
Figure 1: Unbound fraction (fu) of moxifloxacin in plasma of
ICU patients with sepsis treated with moxifloxacin 400 mg i.v.
once daily
Median, IQR, circles = mean values of 6 samples per patient,
dotted line = fu in pool plasma from healthy volunteers
The unbound fraction was higher than the value of
58–60% provided by the manufacturer (Fachinformation
Avalox 400 mg/250 ml Infusionslösung, date 06/2015,
Bayer Vital, Leverkusen, Germany). In order to explain
the discrepancy, the influence of experimental variables
such as temperature and pH were investigated. Temper-
ature had a slight influence on the unbound fraction of
moxifloxacin which increased from 77% at 5°C to
85–86% at 25–37°C (Figure 2).
Figure 2: Influence of temperature on the protein binding of
moxifloxacin in human plasma, buffered with potassium
phosphate to 7.4, as determined by ultrafiltration. Mean±SD
of 4 independent experiments withmoxifloxacin 3 or 0.3mg/L
(n=8)
To examine the influence of pH, plasma was spiked with
moxifloxacin 3 or 0.3 mg/L and buffered with potassium
phosphate, HEPES or TRIS to pH ranging from 7.0 to 8.5
as described recently [10]. For comparison, unbuffered
plasma was analysed as well. The unbound fraction was
79–84% at pH 7.0 to 7.4 and decreased to 66–68% at
pH 8.5 or in unbuffered plasma (Figure 3).
Figure 3: Influence of pH on the protein binding ofmoxifloxacin
in human plasma (at 37°C) as determined by ultrafiltration.
Mean±SD of 4 independent experiments with moxifloxacin
3 or 0.3 mg/L (total n=8)
Abbr.: P phosphate, H HEPES, T TRIS, Pl plasma unbuffered
3/6GMS Infectious Diseases 2017, Vol. 5, ISSN 2195-8831
Dorn et al.: Decreased protein binding of moxifloxacin in patients ...
Discussion
Antiinfective drugs are commonly evaluated on the basis
of pharmacokinetic/pharmacodynamic (PK/PD) indices,
all of which are based on a comparison of its plasma
concentrations and the minimal inhibitory concentration
(MIC) against the pathogen. However, plasma protein
binding affects the antimicrobial activity of fluoroquino-
lones [11]. Consequently, all PK/PD indices should refer
to the unbound (non-protein bound) fraction of a drug
[12]. In addition, the concentrations in the interstitial
fluid are considered to equal the free plasma concentra-
tions. Therefore, it was reasonable to determine not only
the concentrations of moxifloxacin in the intersitial fluid
in the present microdialysis study, but also the free
plasma concentrations in a subset of plasma samples.
The plasma protein binding of moxifloxacin in man is
about 40% according to the SPC and previously published
data [11], [13], [14]. Our results indicate a lower plasma
protein binding of moxifloxacin in patients with sepsis.
Hypoalbuminaemia is often observed in critically ill pa-
tients [15], [16] and is readily used to explain reduced
protein binding in such patients [16]. However, the protein
binding of moxifloxacin in plasma of healthy volunteers
was also about 15% only. On the other hand, the mean
unbound fraction of moxifloxacin was lower in plasma
buffered to pH 8.5 or in plain plasma, where the pH raises
above 8 or reaches even 9 after preparation and storage
[17]. This behaviour is typical for basic drugs which be-
come more lipophilic at alkaline pH [17]. Accordingly, no
pH dependency has been observed with neutral antimi-
crobials such as linezolid or fluconazole [10], whereas
the protein binding of tigecycline, a tetracycline with an
excess of amino functions, increases dramatically at pH>8
[18]. Fluoroquinolones are zwitterions andmost lipophilic
at the isoelectric point, which is 8.0 for moxifloxacin. This
unusual high isoelectric point of moxifloxacinmay explain
the higher protein binding of moxifloxacin at elevated pH.
Accordingly, also the penetration into the alkalotic human
prostate secret was highest for moxifloxacin compared
with other fluoroquinolones [19]. To sum up, strict pH
and temperature control is necessary when studying
protein binding [17]. There are numerous publications
reporting and discussing data that have been produced
without sufficient control of these parameters [17] includ-
ing moxifloxacin [11], [20]. There is one publication re-
porting a protein binding of 54±14% in human serum
despite adjusting the pH to 7.0–7.5 and pre-incubation
of serum at 37°C [14]. However, hydrochloric acid has
been used for pH adjustment, which has no buffer prop-
erties at physiological pH. Moreover, the high coefficient
of variation (26%) indicates that the method used was
imprecise and presumably not reliable. To sum up, it
should be appropriate to assume an unbound fraction of
moxifloxacin of 85% in man concerning PK/PD calcula-
tions [12].
We use phosphate buffer in our standard procedure [9]
in analogy to the buffer system used in equilibrium dialys-
is [21], which still is considered as “gold standard” for
the determination of free drug concentrations [22].
However, experiments with tigecycline revealed a signifi-
cant higher unbound fraction, when the plasma was
buffered with phosphate compared with HEPES [18]. We
assigned this observation to competition for calcium
between phosphate and tigecycline. It is well known that
besides tetracyclines also fluoroquinolones form chelate
complexes with multivalent metal ions [23], [24]. As a
surprising consequence of the complex formation
between tetracyclines or fluoroquinolones and calcium,
lower plasma concentrations of tigecycline and ciprofloxa-
cin were measured when blood was collected in EDTA-
coated tubes instead of heparin-coated tubes. Obviously,
EDTA binds plasma calcium. As a consequence, non-
chelated tigecycline or ciprofloxacine diffuse into the
blood cells thus lowering their plasma concentrations
[25]. Moreover, as calcium binds to albumin in a pH de-
pendent manner [26], interference of phosphate buffer
with the protein binding of drugs such as tetracyclines or
fluoroquinolones is conceivable. Concerningmoxifloxacin,
the difference of the unbound fraction in phosphate or
HEPES buffered plasma was statistically significant but
small (84 vs 79%) and clinically irrelevant. In addition,
one has to take into account that the pH cannot be exactly
maintained at 7.4 either with phosphate or with HEPES.
There is a small drift (ca. 0.3 pH units) upwards during
ultrafiltration for 20 min at 37°C with phosphate [9] due
to evaporation of carbon dioxide. Furthermore, HEPES
shows a negative pH drift with temperature in contrast
to phosphate [27]. Therefore, the statistically significant
difference may partly be explained by differences in the
actual pH during ultrafiltration in phosphate and HEPES
buffered plasma, respectively.
Conclusion
The clinical relevance of the apparently higher unbound
fraction of moxifloxacin as claimed in our study (85%
compared with 60% as provided in the SPC) may be lim-
ited. However, as all PK/PD indices should be referenced
to the unbound (non-protein bound) fraction of the drug
[12], the conclusions from published studies using the
50–60% values would be slightly different. For example,
the 90% probability of target attainment (fAUC/MIC=100
for Gram-negative pathogens) in patients with diabetic
foot infections was achieved for pathogens with
MIC≤0.125 [4]. Taking an unbound fraction of 85% as
basis, a slightly more favourable MIC≤0.18 would result.
Moreover, based onmicrodialysis experiments, themean
ratio of AUCtissue/fAUCplasma in patients or healthy subjects
was calculated between 0.7 and 1.2 [6], [28], [29] which
would change to 0.45 and 0.75.
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